Article Figures & Data
Figures
- Figure 1.
Average inhibition rate (IRs) of tumors for drugs in the HDRA for 104 ovarian cancer. BLM: Bleomycin; VP16: etoposide; ADR: adriamycin; TOP: topotecan; GEM: gemcitabine; lFS: ifosphamide; BEL: belotecan; CDDP: cisplatin; DTAX: detaxel; CBP: carboplatin.
- Figure 2.
Kaplan–Meier survival curves showing progression-free survival of patients sensitive to both taxol and carboplatin (SS group, n=24), and patients not sensitive to either drug (R group, n=49). The median PFS was longer in the SS group than in the R group (34.0 vs. 16.0 months, p=0.03).
- Figure 3.
Kaplan–Meier survival curves showing overall survival of patients sensitive to both taxol and carboplatin (SS group, n=24), and those not sensitive to either drug (R group, n=49) (p=0.27).
Tables
In this issue
Progression-free Survival Is Accurately Predicted in Patients Treated with Chemotherapy for Epithelial Ovarian Cancer by the Histoculture Drug Response Assay in a Prospective Correlative Clinical Trial at a Single Institution
Jump to section
Related Articles
Cited By...
- Assessment of the Applicability of Integrative Tumor Response Assays in Advanced Epithelial Ovarian Cancer
- Clinical Significance of 5-Fluorouracil Chemosensitivity Testing in Patients with Colorectal Cancer
- Correlation Between 18F-FDG-uptake and In Vitro Chemosensitivity of Cisplatin in Head and Neck Cancer
- Independence of Cytotoxic Drug Sensitivity Profiles and Receptor Subtype of Invasive Ductal Breast Carcinoma Demonstrated by the Histoculture Drug Response Assay (HDRA)
- Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines